2Wu J, Fang HH, Chen JT, et al. Immunogenicity, safety and crossreactivity of an inactived, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase H double-blind, randomized trial. Clin Infect Dis,2009,48(8) : 1087-1095. 被引量：1
3Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet, 2010,375 (9708) : 56-66. 被引量：1
4Zhu FC, Wang H, Fang HH, et al. A novel influenza A(H1N1) vaccine in various age groups. N Engl J Med, 2009, 361 (25) : 2414-2423. 被引量：1
4Commission of the European Communities. Harmonizationof requirements for influenza vaccine [ S ]. EEC Document II1,1991. 被引量：1
5CDC US.Assessment of the Effectiveness of the 2003-2004 Influenza Vaccine Among Children and AdultsColorado, 2009[J]. MMWR,2004,53 (31 ):707-710. 被引量：1
